Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TRXADE HEALTH, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/09/2021 | 08:33am EDT

Item 7.01 Regulation FD Disclosure.

TRxADE HEALTH, INC.'s (the "Company", "we" and "our") management plans to hold virtual roadshows and meetings with current and prospective investors, funding sources, and others and to attend certain virtual conferences, from time to time, including attending the virtual conferences discussed below:

Colliers 5th Annual Investor Conference

Date: Thursday, September 9, 2021

Available for One-on-One Meetings

Location: Virtual

H.C. Wainwright 23rd Annual Global Investment Conference

Date: Monday, September 13, 2021

On-Demand Presentation Available From: 7:00 a.m. Eastern time

Webcast: https://journey.ct.events/view/d00f549f-194a-4baa-91a8-dfb17498f9c1

Available for One-on-One Meetings

Location: Virtual

Benzinga Healthcare Virtual Conference

Date: Wednesday, September 29, 2021

Time: 3:00 p.m. Eastern time (12:00 p.m. Pacific time)

Webcast: https://www.youtube.com/watch?v=KS30Mcu5ei8

Location: Virtual

A copy of the presentation which the Company will use in connection with such conferences, roadshows and meetings is being furnished as Exhibit 99.1 to this Current Report on Form 8-K, and is also available on the Company's website at https://investors.trxadegroup.com/nasdaq-meds/presentations-nasdaq-meds/, which website includes information the Company does not desire to incorporate by reference into this report.

On September 7, 2021, the Company issued a press release providing information regarding the conferences discussed above, a copy of which is included herewith as Exhibit 99.2.

The information responsive to Item 7.01 of this Form 8-K and Exhibits 99.1 and 99.2, attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this Report is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.

The Presentation and press release attached hereto as Exhibits 99.1 and 99.2, respectively, contain certain statements that may be deemed to be "forward-looking statements" within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). You can identify these forward-looking statements by words such as "may," "should," "expect," "anticipate," "believe," "estimate," "intend," "plan" and other similar expressions. Forward-looking statements are not a guarantee of performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and are beyond our control. These risks and uncertainties should be carefully considered. We caution you not to place undue reliance on the forward-looking statements, which involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. The forward-looking statements contained in Exhibits 99.1 and 99.2 are made as of the date of the Presentation and press release attached hereto as Exhibit 99.1 and 99.2, respectively. We disclaim any obligation to update any of these forward-looking statements as a result of new information, future events, or otherwise, except as expressly required by law.

The links to the webcast websites above are provided for informational purposes only and we make no representations regarding such websites, the information thereon, or any links accessible therefrom, and do not desire to incorporate any of the information on, or accessible through, such websites into this report.

Item 9.01. Financial Statements and Exhibits.

No.       Description

99.1*       TRxADE HEALTH, INC. - August 2021 PowerPoint Presentation
99.2*       Press release dated September 7, 2021
104       Inline XBRL for the cover page of this Current Report on Form 8-K

* Furnished herewith.

© Edgar Online, source Glimpses

All news about TRXADE HEALTH, INC.
09/28TRXADE HEALTH : to Present at LD Micro Main Event on October 12, 2021
09/09TRXADE HEALTH, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
09/07TRXADE HEALTH : to Present at Upcoming Investor Conferences in September
08/10TRXADE HEALTH : Bonum Health, a TRxADE Company, Launches Pre-Paid Digital Telemedicine Pas..
08/06TRXADE HEALTH, INC : Entry into a Material Definitive Agreement, Other Events, Financial S..
07/27SECTOR UPDATE : Health Care Stocks Gain Amid Broad Market Losses; Biotechs Wilt
07/27SECTOR UPDATE : Health Care Stocks Back on Positive Ground This Afternoon
07/27Wall Street Treads Water Pre-Bell, Fed Meeting in Focus
07/26TRXADE : Q2 Earnings Snapshot
More news
Analyst Recommendations on TRXADE HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 9,22 M - -
Net income 2021 -5,35 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,89x
Yield 2021 -
Capitalization 36,8 M 36,8 M -
Capi. / Sales 2021 3,99x
Capi. / Sales 2022 2,52x
Nbr of Employees 43
Free-Float 40,5%
Duration : Period :
TRxADE HEALTH, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRXADE HEALTH, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 4,51 $
Average target price 8,67 $
Spread / Average Target 92,2%
EPS Revisions
Managers and Directors
Surendra Ajjarapu Chairman, Chief Executive Officer & Secretary
Prashant Patel President, Chief Operating Officer & Director
Howard A. Doss Chief Financial Officer
Jeff Davis Senior System Architect & Systems Engineer
Donald G. Fell Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEITUAN-3.05%221 095
SHOPIFY INC.31.25%183 340
PINDUODUO INC.-45.11%121 569
MERCADOLIBRE, INC.-4.93%118 987